3651 results for «211»
3651 results
Challenging clinical scenarios in STEMI
21 May 2026 – From EuroPCR 2026
This session explores challenging clinical scenarios in STEMI, including coronary embolisation from aortic valve vegetation, blunt chest trauma-related STEMI, intramural hematoma diagnostics with multimodality imaging, acute stent thrombosis during dengue recovery, and advanced clot removal techniques beyond standard aspiration devices.
TAVI procedural complications - Part 9: coronary occlusion, difficult aortic valve crossing and more
21 May 2026 – From EuroPCR 2026
Explore the management of complex TAVI procedural complications, including coronary occlusion and difficult valve crossing. This session presents innovative bailout techniques, diagnostic challenges, and case-based discussions highlighting acute coronary syndrome post-TAVI and nuanced approaches to valve-in-valve interventions.
Mitral valve-in-valve, valve-in-ring, valve-in-mac: the good, the bad and the ugly
20 May 2026 – From EuroPCR 2026
This session delves into the complexities of mitral valve interventions, focusing on valve-in-valve, valve-in-ring, and valve-in-mitral annular calcification (MAC) procedures. It addresses troubleshooting in high-risk valve-in-MAC cases, urgent transcatheter mitral valve implantation supported by microaxial flow pumps, challenges in delivering balloon expandable valves transeptally, and innovative...
Mitral interventions: procedural risk assessment and interventions
21 May 2026 – From EuroPCR 2026
Focused on mitral valve interventions, this session covers procedural risk assessment and outcomes following transcatheter edge-to-edge repair (TEER). Topics include predictive risk scores, technical complexity, pulmonary artery pressure indices, right ventricle-pulmonary artery coupling, and novel imaging predictors influencing procedural success and patient prognosis.
Complex distal LM PCI challenges (trifurcations and more)
20 May 2026 – From EuroPCR 2026
Focusing on the intricacies of complex distal left main PCI, this session covers challenging trifurcation lesions and emergency interventions. It includes IVUS-guided approaches for trifurcation PCI, management of calcified left main trifurcations, and multidisciplinary team rescue strategies for unstable left main bifurcation disease.
Inflammation and cardiovascular risk
21 May 2026 – From EuroPCR 2026
Exploring the interplay between inflammation and cardiovascular risk, this session reviews contemporary research on residual risk post-PCI, inflammatory markers in coronary artery disease especially in type 2 diabetes and ACS, and prognostic tools including lipoprotein(a) and systemic inflammation indices.
Images that speak for themselves
20 May 2026 – From EuroPCR 2026
This visually-driven session presents compelling clinical cases where imaging played a decisive role. Cases include unexpected challenges following transcatheter tricuspid valve replacement, severe hypertension in a young athlete, atypical coronary artery anatomy, critical moments of cardiac arrest, and unique coronary artery findings resembling a spider web.
Modern risk prediction in TAVI
21 May 2026 – From EuroPCR 2026
This session examines modern risk prediction models in transcatheter aortic valve implantation (TAVI). It presents novel scoring systems, the prognostic significance of cardiac damage extent and progression, and the impact of multivalvular disease, enhancing patient stratification and outcome prediction.
PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...
INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes
03 Sep 2024
Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.
Author
BioCardia reports positive interim results from phase III CardiAMP cell therapy heart failure trial, with compelling data in subgroup with elevated NTproBNP biomarker for heart failure.
04 Mar 2024